,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Mr. Alfred F. Altomari', 'age': 63, 'title': 'Chairman, Pres & CEO', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 644396, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
1,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Mr. Geoffrey P. Gilmore', 'age': 56, 'title': 'Sr. VP & Chief Admin. Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 478920, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
2,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Dr. Paul  Korner M.B.A., M.D.', 'age': 56, 'title': 'Sr. VP & Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 480402, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
3,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Mr. Scott M. Coiante', 'age': 55, 'title': 'CFO, Sr. VP & Treasurer', 'yearBorn': 1967, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
4,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Matthew  Riley', 'title': 'Head of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
5,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Mr. Robert G. Conway M.E.', 'age': 64, 'title': 'Sr. VP and Chief Corp. Planning & Supply Chain Officer', 'yearBorn': 1958, 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
6,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H.', 'age': 54, 'title': 'Consultant', 'yearBorn': 1968, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
7,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': 'Ms. Amy  Welsh', 'age': 51, 'title': 'Sr. VP & Chief Commercial Officer', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
8,500 College Road East,Suite 310,Princeton,NJ,08540,United States,609 683 1880,https://www.agiletherapeutics.com,Drug Manufacturers—Specialty & Generic,Drug Manufacturers—Specialty & Generic,Healthcare,Healthcare,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.",22,"{'maxAge': 1, 'name': ""Joseph  D'Urso"", 'title': 'Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",10,6,8,8,8,1693526400,1672444800,86400,4,2.07,2.04,2.01,2.09,2.07,2.04,2.01,2.09,0.0,1.12863,0.015378955,-0.19,35734,35734,51454,40730,40730,2.0,2.08,1000,800,4026405,2.0,19.2,0.24682187,2.5189,7.428945,0.0,0.0,USD,3819815,-1.1681501,1800015,1926510,10652,38475,1690761600,1693440000,0.0055,0.034089997,0.0104,0.24,0.0055,1926510,-7.387,1672444800,1703980800,1688083200,-19056000,135.9,-11.0,1:50,1681171200,0.234,-0.148,-0.88641304,0.14113986,NCM,EQUITY,AGRX,AGRX,"Agile Therapeutics, Inc.","Agile Therapeutics, Inc.",1400851800,America/New_York,EDT,5b2c438d-132e-372c-9ee5-2d843d08809d,finmb_858721,-14400000,2.09,250.0,250.0,250.0,250.0,3.0,hold,1,2785000,1.446,-25755000,2694000,0.473,0.761,16313000,15.307,-0.72398,-19908624,-28376000,1.588,0.54710996,-1.5788001,-1.6119701,USD,
